Mather Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Mather Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.69K	Sell	11 -15	-58%	-$3.82K	﹤0.01%	1972
2026 Q2	$7.88K	Buy	26 +15	+136%	+$4.52K	﹤0.01%	1542
2026 Q1	$3.7K	Buy	+11	New	+$3.74K	﹤0.01%	1622
2025 Q4	–	Sell	-14	Closed	-$6.55K	–	679
2025 Q3	$6.55K	Buy	+14	New	+$5.7K	﹤0.01%	1341
2025 Q2	–	Sell	-20	Closed	-$5.42K	–	649
2025 Q1	$5.42K	Buy	20 +8	+67%	+$2.06K	﹤0.01%	1391
2024 Q4	$2.82K	Buy	12 +6	+100%	+$1.58K	﹤0.01%	1479
2024 Q3	$1.54K	Sell	6 -4	-40%	-$1.04K	﹤0.01%	1518
2024 Q2	$1.49K	Buy	10 +3	+43%	+$474	﹤0.01%	1955
2024 Q1	$1.34K	Buy	+7	New	+$1.17K	﹤0.01%	1594

Other funds holding ALNY

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Portman Square Capital London, United Kingdom $1.77B AUM 15.29% 1-Year Est. Return

Fideuram - Intesa Sanpaolo Private Banking Turin $3.5B AUM 45.13% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12.3B AUM 33.99% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.8B AUM 30.39% 1-Year Est. Return

Mather Group's ALNY Position: Q3 2026 in Review

Mather Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 58% in Q3 2026, selling an estimated $3.82K and leaving 11 shares worth $2.69K. The position accounts for ﹤0.01% of the portfolio, ranked #1972.

Mather Group first reported a position in ALNY in Q1 2024 and has held it in 9 quarters since. The position peaked at $7.88K in Q2 2026. 123 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

Mather Group held 11 shares of Alnylam Pharmaceuticals worth $2.69K as of Q3 2026.
Mather Group sold 15 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $3.82K.
Alnylam Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1972 holding.
Mather Group first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Mather Group's Alnylam Pharmaceuticals position peaked at $7.88K in Q2 2026.
123 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.